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                                                                      Introduction
Breast  cancer  is  the  leading  cancer  in  women  . Breast  cancer  is  the  most 
common cancer in women, accounting for a total of 215,990 cases and 39,800 deaths per 
year  in  United  States[18].  Worldwide,  nearly  1  million  cases  are  seen  annually. 
Epidemiologists have calculated that a woman born today in the United States has a 1 in 
8 chance of developing breast cancer in her life time and the life risk of dying from 
breast cancer is 3.3% or 1 in 30 women.
In India,  breast  cancer  is  second most  common cancer among women next  to 
cervical  cancer.   In  Chennai,  according to  2004 statistics,  the  most  common cancer 
among women is breast cancer 26.5%, the next common is cervical cancer 21.2% and 
the others are ovary, stomach, and oral cancers. The crude ratio and age adjusted ratio 
per 100000 population for developing breast cancer is 24.4 and 26.6[19].
          Most patients presented with locally advanced breast carcinoma. Ratio of locally 
advanced  breast  cancer  (LABC)   to  early  breast  cancer,  in  our  centre,  is  70:30,as 
0pposed to Western statistics where LABC accounts to less than  20%.
Neoadjuvantchemotherapy  (adjuvant  /  Basal  /  Induction  /  Primary  /  Preoperative 
Chemotherapy) is given preoperatively in LABCs to give a tumor size reduction and a 
better surgical approximation.
The  role  of  imaging  for  patients  treated  with  neoadjuvant  therapy  for  breast 
cancer is not only to evaluate the therapeutic response in terms of tumour shrinkage, but 
also to predict the histological response to chemotherapy, which is correlated to survival. 
Surgery  and histopathological  analysis  after  neoadjuvant  therapy  allow for  an 
objective assessment of the accuracy of imaging techniques in evaluating response.  A 
complete  tumour  response  to  neoadjuvant  chemotherapy  increases  the  disease-free 
interval and patient survival.
The  parameter  with  the  greatest  predictive  value  is  the  absence  of  any  gross 
residual tumour. Limited microscopic residual tumour does not play any significant role, 
and is found nearly constantly (95% of complete responses).
Assessing response to neoadjuvant chemotherapy in breast cancer is important, 
because  a  nonreponsive  tumor  can  be  combatted  with  a  higher  or  different  set  of 
chemotherapeutic agents, thereby preventing adverse effects of chemotherapy regimen 
and saving time by timely change of regimen and getting a response to treatment. A 
complete  tumour  response  to  neoadjuvant  chemotherapy  increases  the  disease-free 
interval  and  patient  survival.  Hence  assessing  the  response  also  prognosticates  the 
patient’s  disease- free survival.    
Physical examination is often unsatisfactory for assessment of the response of 
Locally advanced breast cancer to primary medical treatment.
Feldman  et al.  [1] reported    That  45% of complete clinical responders had 
macroscopic tumour at histological examination; inversely, 60% of patients without any 
histological gross residual tumour had an incomplete clinical response. In the series of 
49 patients studied by Cocconi et al. [2].
Physical  examination  overestimated  tumour  regression  in  23%  of  cases  and 
underestimated the response in 9%. The accuracy of physical examination is mediocre 
because palpation of a fibrotic and necrotic mass may mimic a residual tumour mass. In 
other  cases,  the  apparent  clinical  regression  is  due  to  resolution  of  post-biopsy 
phenomena  such  as  haemorrhage  and  oedema.  Tumours  in  a  progressive  phase  are 
difficult to assess by physical examination; regression of inflammatory phenomena is 
often the sole objective parameter as the tumour mass itself changes very little.
In the series of Balu-Maestro  et al. ,(3) ultrasound has been found to be poorly 
reliable,  evaluating the size  of  residual  tumour  after   chemotherapy only in 43% of 
cases. In other series  ultrasound was found to be superior to physical examination and 
mammography especially when the tumour was hypoechoic. Modification of tumoral 
echogenicity induced by chemotherapy limits the reproducibility of the measurements 
after treatment. 
During the treatment the tumoral density decreases on successive mammograms. 
This  density  diminution  cannot  be  measured  and  may  even  interfere  with  the 
measurements  because  of  the  decreased  contrast  ratio  between  tumoral  and  normal 
tissue. Ultrasound may then be more reliable. 
When the tumour is fractionated, plurifocal, or when it is larger than the field of 
the probe, the ultrasound measurements are not so reliable. In multifocal disease, the 
advantage of ultrasound is controversial. Infra-clinical or infra-mammographic lesions 
may be found that will change the therapeutic strategy but will not be characterized with 
certainty by this method. Ultrasound is able to measure the skin thickness and oedema 
and to  follow their  evolution.  Ultrasound is  the  best  modality  for  examining lymph 
nodes (sensitivity 72%–84%, specificity up to 97%  with high frequencies probes) [5,6]. 
Controversial  results  about  ultrasound  in  the  literature  emphasize  the  importance  of 
parameters that interfere with the accuracy of the method.  The main one is operator 
dependence.  However,  the  technique  is  changing  and  must  not  remain  only 
morphological especially in monitoring treatment of cancers.
An early decrease or disappearance of tumour vascularity evaluated by Doppler 
ultrasonography  may reflect  the efficiency of chemotherapy before any decrease in 
tumour  volume.  On the  contrary,  an  increase  in  tumour  vascularity  reflects  tumour 
progression.
MRI allows morphological analysis of tumours and kinetic study of the contrast 
enhancement reflecting the richness of the vascularization. It is the most reliable method 
for appreciating multifocality. Its role is essential in pre-therapeutic staging and in the 
assessment of chemotherapy efficacy. 
Most authors find an excellent correlation between the macroscopic tumour size 
and the tumour established by MRI.
In the series of Abraham et al. [8], in 97% of the cases, the results of MRI after 
treatment correlated with the pathological findings.
During or after neoadjuvant chemotherapy, role of MRI is to (a) monitor early 
response to treatment (b)identify possible residual disease.
To avoid harm and costs  due to inefficient  treatment it  is  desirable to predict 
response to Neoadjuvant chemotherapy as early as possible, ideally immediately after 
the first cycle. Imaging  at this stage is aimed at demonstrating a metabolic response to 
treatment ,like  change in contrast  enhancement  and time activity  curve  ,rather  than 
change in tumor size. Since assessing response to chemotherapy shall have substantial 
impact on clinical decision –making, it may emerge as one of the important indications 
of breast MRI.[17].
To  obtain  more  and  higher  level  evidence  for  this  indication  The  American 
College  of  Radiology  imaging  network(ACRIN)  has  sponsored  a  multiinstitutional 
prospective trial (ACRIN 6657) to evaluate the role of MR in predicting response to 
treatment.[17]
In our study we have studied the response of neoadjuvant chemotherapy to locally 
advanced breast cancer by dynamic contrast enhanced MR mammogram and compared 
its efficacy with post surgical histopathology results.
MR MAMMOGRAM–HISTORY OF DEVELOPMENT AND TECHNIQUES
Limitations of conventional breast assessment
Includes the combination of screen-film X-ray mammography, high-resolution breast 
ultrasonography  (US),  and  clinical  breast  examination  leads  to  the  detection  of 
approximately 85-90% of breast malignancies, and it forms the foundation of modern 
strategies for breast cancer detection. The results of this assessment also serve as the 
final arbiter for the use of breast biopsy in breast screening programs worldwide. 
Limitations of conventional breast assessment
Despite cases in which conventional assessment fails  to depict  a  breast malignancy 
accurately, as in 1 of the following scenarios. 
Palpable lesion without a focal imaging correlate. 
So-called interval cancers that are missed or not visible on initial images. 
Understaging of the extent of the lesion or multifocality in the same or opposite breast. 
Patient presenting with distant or axillary breast cancer metastasis with no breast lesion 
found on mammograms or sonograms. 
Chest wall invasion that is not detected.
Inaccurate  clinical  assessment  of  large  tumors  that  are  treated  with  neoadjuvant 
chemotherapy.
Development of breast MRI 
Combination of rapid 2D gradient-echo (GRE) imaging with a dedicated breast coil, 
coupled with the bolus injection of gadolinium dimeglumine (Kaiser, 1989) that created 
the technique of dynamic contrast-enhanced breast MRI. 
This technique showed an extremely high sensitivity for breast malignancy, which in 
some cases exceeded that of conventional imaging.
Although this technique was initially limited to a single section location, it was 
soon modified with newly developed multisection spoiled GRE sequences, with 
no  loss  of  sensitivity.  This  still  forms  the  foundation  of  modern  breast  MRI. 
Indications for MR MAMMOGRAM 
 As a screening tool:
High risk screening
Screening women with dense breast tissue
 As a diagnostic tool: 
To look for occult lesion
To look for multicentricity
 As a staging tool:
To assess chest wall invasion
 As a prognostic tool:
Assess neoadjuvant chemotherapy response
To look for residual disease if tumor margins are not free
To diff scar from recurrence 
 Contraindications to MRM 
Contraindication  to  gadolinium-based  contrast  media  (eg,  allergy,  pregnancy,  renal 
failure etc)
Patient's inability to lie prone 
Marked kyphosis or kyphoscoliosis 
Marked obesity 
Extremely large breasts
Severe claustrophobia
EQUIPMENT
MRI with field strength with more than 1 tesla
Low-field-strength magnets lack the gradient subsystems required for high-speed, 
high-resolution volumetric (3D) images, which are now considered essential for 
the detection of small lesions and for architectural evaluation.
BREAST COIL
A dedicated double breast surface coil is essential because it permits 
simultaneous high-resolution, high-quality imaging of 1 or both breasts. With 
patients lying prone with both breasts freely suspended in these coils. Such 
breastcoils should have excellent homogeneity with minimal image shading 
and hot spots; otherwise some regions show low signal intensity and poor 
enhancement, and fat suppression may be unpredictable.
CONTRAST AGENT
Any ECF contrast  agent-Gd meglumine,  gadodiamide,  gadoteric   acid  agents. 
Given contrast agents as rapid bolus injection   at 2ml/sec followed by 20ml NS flush a 
dose of 0.16 mmol/kg appears to provide better sensitivity for lesion detection compared 
with the standard dose of 0.1 mmol/kg at field  strengths less than 1.0 T (Heywang-
Köbrunner, 1994).
Injection timing is important for MRM.Aim to acquire  post contrast data within 
1-2 min.
AXIAL, SAGITTAL, CORONAL-The acquisition plane has a significant  impact 
on  the  pulse  sequence.  Phase-direction  motion  artifacts  due  to  breathing  and  heart 
motion  are  minimized  by  ensuring  that  the  frequency-encoding  direction  is  in  the 
anteroposterior direction for axial and sagittal imaging. 
ACTIVE FAT SATURATION OR SUBTRACTION?[20]
Active fat suppression or fat suppression means the signal from fatty Tissue is 
specifically eliminated(‘knocked out’) by additional Radio frequency pulses or by 
choosing  water  selective  acquisition.  Both  types  take  extra  acquisition  time, 
therefore difficult to reconcile with dynamic protocols.
Subtraction  does  not  require  extra  acquisition  time  and  is  not  influenced  By 
magnetic field inhomogeneities, which is why it is the preferred type of fat suppression 
for bilateral imaging. The main disadvantage of subtraction is that it may suffer from 
patient motion. Subtraction errors occur if precontrast images are not entirely congruent 
with post contrast images, even due to subtle patient motion. Breast immobilization is 
achieved  by  gently  fixating  (not  compressing)  the  breast  in  the  section  encoding 
direction. This is mediolateral direction for sagittal protocols and craniocaudal direction 
for  transverse  protocols.  Compression  should  be  avoided  because  it  may  reduce 
enhancement of breast cancers.[21].
BIRADS MRI imaging lexicon
All suspicious areas are defined as:
Focus/foci  -  <5mm
Mass - 3D space occupying lesion with convex margin
Non mass enhancement
 Further characterisation of mass
Shape (round/oval/lobular/irregular)
Margin (smooth/irregular/spiculated)
Internal enhancement pattern (homogeneous/ heterogeneous/ rimlike/ central/septal)
 Further characterisation of non-mass lesion
Distribution (focal/ multifocal/ linear/ ductal/ regional/ segmental)
Internal enhancement (homogeneous/ heterogeneous/ stippled/ clumped/ reticular)
 Morphologic criteria for malignant processes
Irregular margin
Spiculated
Thick irregular rim enhancement
Segmental non mass enhancement
Lacelike/dendritic pattern of enhancement in inflammatory Carcinoma
Other features: focal perilesional edema & architectural distortion
 Enhancement kinetics
3 types
Type 1 curve: progressive enhancement (80% associated with benignity)
Type  2  curve:   plateau  pattern-initial  increase  followed  by  flattening 
(suspicious for malignancy)
Type  3  curve:   washout  pattern-brisk  increase  followed  by  rapid 
washout(80% associated  with malignancy)
 If  early  rapid  enhancement  due  to  neovascularity  were  unique  to  malignant 
tissues, MRM would be the standard in clinical practice today!
Unfortunately, such enhancement is not specific, and several benign conditions 
may  enhance  in  a  fashion  similar  to  cancer.  Conversely,  a  small  percentage  of 
malignancies either enhance identically to benign breast parenchyma, or rarely, they do 
not enhance at all.
Nonmalignant  mimics of malignant enhancement
Cyclical  parenchymal  enhancement-in  the  secretory  phase  of 
menstrual cycle
Fibroadenoma
Sclerosing adenosis
Florid epithelial hyperplasia            
Infection 
Fat necrosis
Post treatment scarring and/or granulation tissue.
Hence MR mammogram is always done in the proliferative phase preferably First 
10 days of menstrual cycle to minimize the normal parenchymal enhancement.
Malignancy that may show benign-type enhancement
Common - Low-grade DCIS 
Uncommon –
High-grade DCIS 
Highly scirrhous IDC 
Invasive lobular carcinoma 
Mucinous carcinoma 
Papillary carcinoma 
Tubular carcinoma
ANATOMY OVERVIEW
Anatomy of breast[10]
The breast is a modified skin gland that develops from the mammary ridge in the 
embryo. It generally lies on the chest wall between the clavicle and the sixth to eighth 
ribs.  Breast   tissue can be found as far  medially as the sternum and laterally to the 
midaxillary line.
Breast tissue is frequently found high in the axilla, occasionally  reaching to its 
apex. The breast lies on top of and lateral to the pectoralis  major muscle, whose muscle 
fibers course obliquely from the ribs to the  humerus.  Since breast  tissue frequently 
wraps around the lateral margin of the pectoralis major muscle, imaging the breast is 
best accomplished using the mediolateral oblique projection. The best way to image the 
most tissue is by positioning the breast such that the plane of compression is parallel to 
the oblique fibers of the free margin of the muscle. This permits maximum traction on 
the  breast  so  that  it  can  be  fully  positioned  over  the  detector  and  comfortably 
compressed. It also permits evaluation of the portion of the breast that lies lateral to the 
muscle and extends up into the axilla.
Recent work at the MGH by Jennifer Rusby, MD, suggests that there are usually 
more than 20 lobes or segments that are defined by the major lactiferous ducts that open 
on the nipple. A lobe (segment) can be thought of as a tree whose trunk, branches, and 
leaves are hollow. These arborizing networks conduct milk from the lobules (the true 
glands  of  the  breast)  to  the nipple.  The lobule  is  actually  the most  proximal  of  the 
structures if direction is the flow of breast secretions (milk), but it is called the terminal 
portion of the duct system. The lobule consists of multiple blunt-ending ductules in a 
cluster like the fingers of a glove. These fingers form the glandular acini of the lobule. 
They are surrounded by specialized connective tissue that differs histologically from the 
stromal connective tissue found in the rest of the breast. 
The acini and specialized connective tissue together form the lobule. A terminal 
duct  and  its  lobule  are  collectively  called  the  terminal  duct  lobular  unit  (TDLU)  . 
TDLUs can be found as immediate branches of the major ducts and are not always at the 
periphery of the ductal networks.
Breast cancer is thought to originate in the terminal duct in the lobule.
One theory is that this is the location of stem cells and that these undifferentiated 
cells are the most likely to develop malignant transformations. 
The breast  is  held together by varying amounts of connective tissue that form 
varying volumes of sheets of tissue known as Cooper's ligaments. Fat is interspersed 
throughout  the  breast  and  surrounds  it  as  subcutaneous  and  retromammary  adipose 
deposits. 

The Vascular Supply of the Breast
Arterial blood flows from the axillary artery through the lateral thoracic artery to 
supply the upper outer quadrant of the breast. The central and medial portions of the 
breast are supplied from perforating branches of the internal mammary artery, which lies 
adjacent to and beneath the sternal border. Branches of the intercostal arteries provide 
blood to the lateral breast tissues, with some blood coming from the subscapular and 
thoracodorsal arteries.Venous drainage is back through the axillary, internal mammary, 
and intercostal veins, providing three major routes for hematogenous metastasis.
Enervation
Nerves  supplying  the  breast  originate  primarily  from  the  anterior  and  lateral 
cutaneous branches of the thoracic intercostal nerves, with some enervation from the 
cervical plexus to the upper breast. The deep pain sensors in the breast appear to be 
variable. 
The Lymphatics of the Breast
For staging purposes and prognostication, axillary lymph nodes are divided into 
three levels. 
Level  I  lymph nodes are lateral  to the lateral  margin of the pectoralis   major 
muscle  and  extend  down  into  the  tail  of  the  breast.  Mammography  can  frequently 
demonstrate the lowest lymph nodes in this portion of the lymphatic chain.
Level II lymph nodes are beneath the pectoralis minor muscle. When an axillary 
dissection is performed, the free margin of the pectoralis major muscle is retracted out of 
the way and preserved, and the pectoralis minor muscle is transected to remove these 
lymph nodes. This is also performed when a modified radical mastectomy is used to 
treat breast cancer.
The level III lymph nodes are medial and superior to the pectoralis minor muscle, 
up to the clavicle.  Data suggest  that  the higher the level  of nodal involvement with 
cancer, the  worse the prognosis.
 
Levels of Axillary lymph nodes
LITERATURE REVIEW
Literature review
Conventional imaging methods (mammography and USG) are not very useful in 
assessment of response to pretreatment or neoadjuvant chemotherapy.
MRI  has  an  established  role  in  assessment  of  response  of  breast  cancer  to 
neoadjuvant  Chemotherapy.Dynamic  contrast  enhanced  (DCE)  MRI  and  FDG  PET 
serve as biomarkers in functional assessment of tumor post chemotherapy.
Retrospective  analysis  of  conventional  imaging  and  physical  examination  was 
done at MD Anderson chemotherapy trials[11].
Table :1 -Correlation of tumor measurements
Table 2: Correlation with pathologic tumor size among published studies.
MRI prior to chemotherapy is accurate than USG or mammogram  in assessing 
especially multifocal  disease  and  DCIS (ductal carcinoma in situ). MRI following 
chemotherapy  performs  equally  accurately  in  assessing  the  response  to  treatment 
compared to USG and mammography.
Table 3- Review of studies 
MRI is  effective  for  measuring  the  degree  of  tumor  response,  but  can   miss 
residual disease ,particularly for good  responders.[12,13,14,15]
Complete response to chemotherapy does not preclude surgery at any cost.
MRI for monitoring accuracy has led to increased interest in using MRI to assess 
response to treatment. DCE MRI used as part of functional imaging.
Measurements  made  to  assess  response  in  MRI-tumor  volume,  tumor 
morphology, vascular heterogeneity.
At the outset we defined a morphologic partial responder as one who exhibits 
1.>50% reduction in actual tumor size 2. decrease in maximal contrast enhancement & 
3. flattening of time-activity curve.
A morphologic complete responder  as one who showed no residual tumor in 
MRI after 3 cycles of chemotherapy.
A patient with Stable disease as one who showed decrease in tumor volume less 
than 50%
A patient with Progressive disease as one who showed increase of  >25% in 
tumor volume.
Functional  measurements  by  MRI  (DCE-MRI,  diffusion  weighted  MRI,  MR 
Spectroscopy)  can  be  used  to  make  quantitative   measurements  of  tumor  biology 
(microvascular permeability ,water diffusion and choline concentration).
TABLE :4
AMERICAN JOINT COMMITTEE ON CANCER STAGING OF BREAST 
CANCER
Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
Tis DCIS) Ductal carcinoma in situ
Tis LCIS) Lobular carcinoma in situ
Tis (Pagets) Pagets disease of the nipple with no tumor
T1 Tumor 2 cm or less in greatest dimension
T1mic Microinvasion 0.1 cm or less in greatest dimension
T1a Tumor more than 0.1 cm but not more than 0.5 cm in 
greatest dimension
T1b Tumor more than 0.5 cm but not more than 1 cm in 
greatest dimension
T1c More than 1 cm but not  more than 2 cm in greatest 
dimension
T2 Tumor  more  than  2  cm but  not  more  than  5  cm in 
greatest dimension
T3 Tumor more than 5 cm in greatest dimension
T4 Tumor of any size with direct extension to chest wall or 
skin, only as described below

Definition  of  locally  advanced  breast  carcinoma  by  stage  grouping  –AJCC 
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TABLE:5-    Definition of LABC
Contd.

AIM OF THE STUDY
AIM OF THE STUDY 
Assessing the response to neo-adjuvant chemotherapy with   dynamic contrast 
enhanced MR mammogram  using
• Tumor size, 
• Contrast enhancement pattern and
• Time–activity curve as parameters, in locally advanced breast cancer.
MATERIALS AND METHODS
Period of study: September 2007 to October 2008.
Patient population: Patients selected for the study would be from stage IIB to 
stage IIIC breast carcinoma. Lumps small enough for the surgeon to give good tumor 
clearance and cancers with metastasis (stage 4) would be excluded from study.
Inclusion criteria 
Patients with locally advanced invasive ductal carcinoma of breast –with 
stage IIB to stage IIIC.
Exclusion criteria
1. All patients with stage less than IIB, or  stage IV.
2. Patients with renal failure (not fit for MR contrast study)
3. Patients with claustrophobia
4. Patients with other contraindications –pacemaker implants etc.
PRE MRI WORK UP: 
Clinical assessment of tumor & lymph nodes by
• Physical examination, 
• X-ray mammogram,
• Sonomammogram and Doppler.
• Assessment  of  renal  function  –blood  urea  and  serum  creatinine  values. 
Institutional  ethical  committee  clearance  was  obtained  before  the  start  of  the 
study and informed consent was obtained  from every patient for use of MRI 
contrast medium.
MR MAMMOGRAM: 
All patients selected for study were subjected to dynamic CE MR 
mammogram before the start of first cycle of chemotherapy (with 5 
flourouracil-600mg/ m2, adriamycin-60mg/m2, cyclophosphamide-600mg/m2)- using 
SIEMENS Magnetom 1.5 Tesla MRI machine with phased array body coil and 
using MR contrast (gadodiamide) in the dose of 0.16mmol/kg. Core biopsy of lesion 
would be done and sent for HPE.
Dynamic CE MR mammogram was repeated after the third cycle of 
chemotherapy (after 2weeks of completion of 3rd cycle). Response to neo 
adjuvant chemotherapy was assessed in terms of tumor size (tumor volume, 
longest tumor diameter), maximal contrast enhancement and  change in 
time-activity curve.
MRI SEQUENCES: 
• T1 axial, sagittal T2,TIRM axial
• 3D GRE sequence –axial
• 3D GRE Sequence with fat saturation(pre contrast)-  axial
• 3D GRE sequence with fat saturation –post contrast
With dynamic study, MR contrast agent (gadodiamide) was given at the dose of 
0.1 mmol/kg of bolus Intravenously into a cannula in the antecubital vein fixed before 
the MRI the contrast was given by hand injection over time of 10 seconds by a single 
radiologist[17],  followed by 20 ml  flush  of  normal  saline,  the patient  would not  be 
moved in or out of magnet for injection to prevent motion  and unnecessary time losses 
in earlypost contrast phase with acquisition beginning within 60 seconds of  start of 
contrast injection, scan was repeated at 2,4,6 & 8 minutes. Comparison of pre & post 
neoadjuvant chemotherapy MR mammogram images was done.
Change  in  tumor  size-percentage  of  reduction  in  tumor  volume  &  longest 
diameter were assessed. Change in maximal contrast enhancement and change in the 
time  activity  curve  were  assessed.  After  3  cycles  of  chemotherapy,  core 
biopsy/mastectomy specimen was  subjected to pathologic study.  The results in MR 
mammogram were compared with pathologic results. 
All 20 were followed up till surgery with histopathological correlation. As per the 
morphologic and enhancement kinetics response criteria the images were analysed by a 
radiologist experienced in breast imaging. 
IMAGE REVIEW AND ANALYSIS
The images were analysed by 2 radiologists with more than 3 years experience in 
breast MR imaging.
Tumor volume was calculated in dynamic contrast enhanced MR image at 120 sec 
of the study using volume assessment software. Tumor volume reduction was assessed 
in the study done after 3 cycles of chemotherapy.
At the outset we defined
 A morphologic partial responder as one who exhibits
1. >50% reduction in actual tumor size
2. Decrease in maximal contrast enhancement &
3. Flattening of time-activity curve.
 A morphologic complete responder  as one who showed no residual tumor in 
MRI after 3 cycles of chemotherapy.
 A patient with Stable disease as one who showed decrease in tumor volume less 
than 50%.
 A patient with Progressive disease as one who showed increase of     >25% in 
tumor volume.
For the time –activity curve, ROI was drawn on the first image of the batch. Care 
was taken no non tumoral area came under the ROI and that entire area of interest was 
within the tumor. The area of interest  taken was  to 0.4  square cm.
RESULTS
Results
5 patients could not be followed up beyond the first cycle of chemotherapy, we 
are excluding them at the outset.  Attrition in our study was 20%. The remaining 20 
women in our study, were in the age range of 33 to 60 years. 
The mean age of our patients was 48.2years. Of the  25, 12 were of stage T4bN1M0. 
3 members were T4a N1 M0.  9 members were of stage T3N1M0.  1 person was of  stage 
T2N1M0.
All patients received chemotherapy within 1 week of 1st MR study. 
Chemotherapy regimen lasted for 63 days with FAC regimen. Follow up MRI was 
done  in  the  range  of  12  to  18  days  following   completion  of  third  cycle  of 
chemotherapy. The interval between follow up MRI and surgery was 7 to 14 days. 15 
out  of  20  patients  were  partial  responders  (75%).3  out  of   20  were  morphologic 
complete responders (15%).2 out of 20 had stable disease (10%).  Out of 20,17,patients 
had Type 3 time activity curve before chemotherapy and 3 had indeterminate or type 2 
curve. 
Following chemotherapy 14 out of 15 with partial response showed flattening of 
time –activity curve to Type 2 curve, Whereas 1 partial  responder showed persistent 
type 3 curve whereas 1 patient with stable disease showed persistent type 3 curve and 
another showed flattening to type 2 curve.
Statistical analysis was done using Student paired test. 
Overall  tumor  volume reduction  was  88% on the  average.  In  responders the 
tumor volume reduced by a mean 91.5+/-135ml.
In  non-responders  the  tumor  volume reduction  was  mean  6.6ml+/-12.6ml.  P 
value =0.03-significant.
Regarding time-activity curve, 93% (14 out of 15 partial responders) showed a 
change of malignant type (type 3) of curve to indeterminate or benign morphology (type 
2  or  1)  following  3  cycles  of  chemotherapy.  1  of  the  2  non-responders  showed  a 
persistent   malignant morphology   of   curve.  The other showed   a response to type 2 
curve.
Out of 3 complete responders, 2 patients correlated with pathologic CR. While 
one patient showed pathologic residual disease. All persons with partial response and 
stable disease also  correlated with  pathology.  
Hence tumor  volume  as  assessed  by  Dynamic  contrast  enhanced  MR 
mammogram was 94%  sensitive  in detecting  residual tumor. The  measurement  of 
tumor volume  had  a  positive  predictive value  of  100% and  negative  predictive 
value   of  33%.
There were no patient characteristics   including  patient  age  and  menstrual 
state  or  tumor  stage  that  predicted  response.
In both   non-responders there was no significant change in  tumor size. All the 
responders a decrease in tumor size was noted Thus decrease in tumor size is the best 
early predictor of  tumor  response. 
The   morphology   of   time-activity   curve   is  a   semi-quantitative  ,  non-
cumbersome   method to  know about   reduction of  neoangiogenesis  of tumor   in 
response  to  neoadjuvant  chemotherapy.  However   the more  complex   quantitative 
kinetic  analyses like  the  transfer constant   are  the only  the  most  reliable  parameters 
to assess   neoangiogenesis, which   was   not  done  in   our  study.
With   time-activity curve, 93% (14 out of 15 partial  responders) showed   a 
change  of    malignant   type (type 3)  of   curve   to    indeterminate   or    benign 
morphology  (type  2  or   1)  following 3  cycles  of  chemotherapy.1  of  the   2    non-
responders  showed  a   persistent   malignant morphology   of   curve.  The other 
showed  a response to type 2 curve.
Hence  the  time  activity  curve  showed  93% sensitivity  in  our  study  to  detect 
tumor response. Whether time activity curve showed functional tumor response before 
reduction in tumor size, we were not able to tell from this study, because imaging was 
not  done   during  the  early  cycles  of  chemotherapy  (eg  after  the  first  cycle  of 
chemotherapy).
TABLE 6:  Chemotherapy regimen, Tumor volume,  Morphologic response &  Pathologic findings.
S. 
No.
Age Stage Chemo 
therapy 
regimen 
Pre 
chemotherapy
Tumor 
volume(ml)
Post 
chemotherapy
Tumor 
volume(ml)
Morphologic
response
Pathologic
Findings
1 47 T4bN1M0 FAC 1575 200 m PR IDC
2 50 T4b N1 
M0
FAC 605 42 m PR IDC
3 45 T4b N1 
M0
FAC 52 18 mPR IDC
4 55 T4b N1 
M0
FAC 198 25 mPR IDC
5 55 T4b N1 
M0
FAC 240 30 mPR IDC,DCIS
6 45 T2N1M0 FAC 8.7 6 mSD IDC,DCIS
7 35 T3 N1 M0 FAC 182 0 mCR IDC
8 70 T4b 
N1M0
FAC 46 25.4 mSD IDC,DCIS
9 33 T4b N1 
M0
FAC 48 4 mPR IDC
10 45 T3N1M0 FAC 2 0 mCR IDC
11 39 T3N1M0 FAC 250 15 mPR IDC
12 42 T3N1M0 FAC 56 0 mCR IDC
13 55 T4b 
N1M0
FAC 40  3   mPR IDC
14 65 T4b  N1 
M0
FAC 42.5 6   mPR IDC
15 42 T4b 
N1M0
FAC 56  14  mPR IDC
16 45 T4b  N1 
M0
FAC 177 20  mPR IDC
17 52 T3 N1M0 FAC 180 1.5 mPR IDC
18 30 T4a  N1 
M0
FAC 535 50 m PR IDC
19 45 T4a  N1 
M0
FAC 190 13 mPR IDC
20 43 T3N1M0 FAC 217 20 mPR IDC
F-5=Flourouracil, A=Adriamycin,  C=Cyclophophamide,  DCIS=Ductal carcinoma in 
situ,  IDC=Infiltrating ductal carcinoma,  mCR=Morphologic complete response, m PR 
=Morphologic partial response,   m SD = Morphologic stable disease
DISCUSSION
DISCUSSION
Assessment of response to locally advanced breast cancers done in our Centre 
where the ratio of Locally advanced breast cancer (LABC) to Early breast cancer is 
70%: 30% patients presented with huge masses-T4 category.
Maximum tumor  diameter  encountered  was  16cm,  maximum  tumor  Volume 
encountered was 1575ml (prechemotherapy).
We  have  used  phased  array  body  coil  to  image  the  breast  in  Assessment  of 
residual tumor in such large masses as we have encountered, DCE MR mammogram 
with  phased  array  body  coil  correlated  well  with  macroscopic  tumor  size  in 
pathology.75% of patients showed partial response in MRI, all of which correlated with 
histopathology. 
Out of 3 persons with morphologic complete response,  2 correlated with HPE 
which showed pathologic complete response.1 person who showed m CR had residual 
disease  in  pathology.  Non-responders  in  our  study  were  10%  for  whom  MRI  and 
pathologic results correlated.
Thus decrease in tumor size is the best early predictor of tumor response. In our 
study, tumor volume as assessed by MR mammogram was 94% sensitive in detecting 
residual tumor. This parameter had a positive predictive value of 100% and negative 
predictive value of 33%.
Results of all research have shown that successful treatment causes decreases in 
rate and magnitude of contrast enhancement and that poor response results in persistent 
abnormal enhancement. 
With   time-activity curve, 17 out initial 20 persons showed type 3 or malignant 
type of time activity curve (85%). 3 out of 20 (15%) type 2 or indeterminate curve. All 
the 17 which showed type 3 curve showed early peak of contrast wash-in within the first 
120  seconds  and  showed  rapid  washout  which  is  typical  of  malignant  contrast 
enhancement kinetics.
        93% (14 out of 15 partial responders) showed a change of   malignant type (type 3) 
of curve to indeterminate or benign morphology (type 2 or 1) following 3 cycles of 
chemotherapy. 1 of the 2 non-responders showed a  persistent  malignant morphology 
of   curve.  The other showed  a response to type 2 curve.
Hence  the  time  activity  curve  showed  93% sensitivity  in  our  study  to  detect 
Tumor response. Whether time activity curve showed functional tumor Response before 
reduction in tumor size, we were not able to tell from this study, because imaging was 
not  done  during  the  early  cycles  of  chemotherapy  (eg  after  the  first  cycle  of 
chemotherapy).
Hence the time activity curve is an non cumbersome parameter to assess early 
functional tumor response to neoadjuvant chemotherapy.
More complex contrast kinetics calculations like the transfer constant etc, which 
are better parameters for reduction in tumor angiogenesis were not assessed in our study.
The causes of the changes in time –activity curve that we observed are likely to be 
multifactorial, relating to both microvessel density and function. 
A  possible  explanation  is  that  successful  chemotherapy  causes  reductions  in 
tumor-angiogenic factors, including VEGF-vascular endothelial growth factor. VEGF is 
a strong stimulus of tumor neoangiogenesis and a potent tissue permeability factor in 
breast cancer [22].
With respect to the vasculature, it is clear that VEGF is also required for vascular 
homeostasis and maintains the high fraction of immature vessels within most tumors. 
Immature vessels  (those without investing pericytes  and/or  smooth muscle  cells)  are 
highly  dependent  on  exogenous  survival  factors,  including  VEGF  [23],  and  these 
immature vessels are by definition the most permeable.Cytotoxic tumor cell death would 
result in a reduction of tissue VEGF production and hence apoptosis of endothelial cells 
in immature vessels.  Endothelial  cell  apoptosis in immature vessels as a response to 
VEGF  withdrawal  has  been  noted  in  a  number  of  treatments,  including 
antiangiogenicand hormonal treatments [24,25,26].
Drug delivery is best to areas of highest microvessel permeability. With high drug 
concentration,  tumor  cell  death  would  result  in  VEGF withdrawal  and  apoptosis  of 
immature vessels, leading to a decrease in contrast enhancement  and change in time 
activity curve.
On the other  hand,  tumor resistance to chemotherapy would result  in ongoing 
production of angiogenic factors that maintain or increase the proportion of immature 
vessels.
TABLE 7:COMPARISON OF MRI versus HPE
HPE POSITIVE HPE NEGATIVE
MRI POSITIVE 19 0
MRI NEGATIVE 1 2
Study limitations 
1. Even  though  imaging  tumor  size  correlated  with  pathology,  not  using  a 
dedicated breast  coil  is  major  limitation in our study,  where we have used 
phased array body coil to cater to the economically deprived population.
2. Attrition rate in our study was 20%.
CONCLUSION
CONCLUSION
MR imaging following neoadjuvant chemotherapy is an important Investigation 
tool to assess early response to neo adjuvant Chemotherapy and to assess residual tumor 
at the end of neoadjuvant Chemotherapy.
Tumor volume is the best early predictor of tumor response. The time activity 
curve  obtained  from  the  dynamic  contrast  enhanced  MR  Mammogram  is  an  early 
functional  parameter  in assessing tumor response to neoadjuvant chemotherapy even 
before any reduction in tumor size occurs. 
Hence  MR  Imaging  can  be  used  to  assess  tumor  response  to  neoadjuvant 
chemotherapy, which is important for clinical decision making, prevents unnecessary 
adverse effects to patients and prevent financial loss.
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GLOSSARY
LABC - Locally advanced breast cancer
mPR - Morphologic partial response
mCR - Morphologic complete response
mSD - Morphologic stable disease
mPD - Morphologic progressive disease
pCR - Pathologic complete response
DCIS - Ductal carcinoma in situ
IDC - Infiltrating ductal carcinoma
MRM - MR mammogram
FAC - 5 flouro uracil, adria mycin, cyclo phosphamide
ROI - Region of interest
PROFORMA: 
 
NAME : 
AGE: 
ONCOLOGY NO: 
ADDRESS: 
 
 
CLINICAL HISTORY: 
  Marital status 
  Obstetric details 
  Pre/postmenopausal 
CLINICAL EXAMINATION: 
   R/L   breast lump    -     Size 
                                         Fixity to skin ,chest wall 
                                         Axillary nodes-number,fixity 
TNM STAGING 
 
 
 
PRE MRI   WORK UP 
                                 
Blood urea 
Serum creatinine 
 
X ray mammogram-size of lump,lymph nodes 
Sonomammogram –size of lump , vascularity, 
                                 number of lymph nodes 
 
 
 
MR  MAMMOGRAM 
 
Size – Dimensions 
           Tumor volume 
Time activity curve 
Lymph nodes 
          
   
 
